UNSPSC 51333507: Clopipazan

This classification denotes an antipsychotic agent with the molecular formula C19H18ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6S9CMY4SE, chemically known as 4-(2-chloroxanthen-9-ylidene)-1-methylpiperidine but generally known as clopipazan, which bears US NIH Compound Identifier 43215. European Medicines Agency schedules Clopipazan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06741MIG. Most nations schedule clopipazan under HS 29349990 and SITC 51579.

As of Q4 2014, CLOPIPAZAN remains the US FDA Preferred Term for this commodity. Clopipazan bears US NLM identifiers UMLS ID C2699376 and NCI Concept Code C79944. SMILES: CN1CCC(=C2C3=CC=CC=C3OC4=C2C=C(C=C4)Cl)CC1.

UNSPSC 51333507 Clopipazan is a Commodity-level code that, based on recent state and local procurement activity, covers pharmaceutical products procured by public health agencies, state health departments, and multistate purchasing cooperatives to support medication access and community health initiatives. The code appears in solicitations for naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established pharmacy supply chains and authorized wholesalers. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving multiple state and local government facilities. State and local buyers of pharmaceuticals under this code typically impose compliance requirements including FDA certification, Drug Supply Chain Security Act (DSCSA) adherence, current Good Manufacturing Practices (cGMP) verification, E-Verify employment authorization, and insurance minimums covering workers' compensation, commercial general liability, and professional liability.

Recent activity spans Florida, Texas, and Minnesota, with a multistate cooperative extending to Oregon. The Seminole County, Florida IFB60459723LAS (posted June 30, 2026, due July 26, 2026) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026) is gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, indicating forward movement on state-level prescription procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (due March 26, 2026) establishes multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities, requiring submission through the ePro system and evaluation weighted 75 percent on price competitiveness, with awarded vendors taking effect July 1, 2026.